Discussion regarding the potential clinical and microbiological outcomes of using a personalized, nebulized bacteriophage therapy strategy. The focus is on selecting phages for predicted evolutionary trade-offs to treat multidrug-resistant Pseudomonas aeruginosa infections in adults with cystic fibrosis.